These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29035637)

  • 21. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor.
    Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M
    Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
    Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epitope characterization of the ADA response directed against a targeted immunocytokine.
    Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
    J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interruption of the HGF paracrine loop by NK4, an HGF antagonist, reduces VEGF expression of CT26 cells.
    Kubota T; Matsumura A; Taiyoh H; Izumiya Y; Fujiwara H; Okamoto K; Ichikawa D; Shiozaki A; Komatsu S; Nakanishi M; Kuriu Y; Murayama Y; Ikoma H; Ochiai T; Nakamura T; Matsumoto K; Nakamura T; Otsuji E
    Oncol Rep; 2013 Aug; 30(2):567-72. PubMed ID: 23722408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conformational flexibility of an anti-IL-13 DARPin†.
    Teplyakov A; Malia TJ; Obmolova G; Jacobs SA; O'Neil KT; Gilliland GL
    Protein Eng Des Sel; 2017 Jan; 30(1):31-37. PubMed ID: 27881684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
    Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
    Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life.
    Yeung YA; Wu X; Reyes AE; Vernes JM; Lien S; Lowe J; Maia M; Forrest WF; Meng YG; Damico LA; Ferrara N; Lowman HB
    Cancer Res; 2010 Apr; 70(8):3269-77. PubMed ID: 20354184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Proline, Alanine, Serine Repeat Sequence for Pharmacokinetic Enhancement of Anti-VEGF Single-Domain Antibody.
    Khodabakhsh F; Salimian M; Mehdizadeh A; Khosravy MS; Vafabakhsh A; Karami E; Cohan RA
    J Pharmacol Exp Ther; 2020 Oct; 375(1):69-75. PubMed ID: 32669367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
    Deyev SM; Oroujeni M; Garousi J; Gräslund T; Li R; Rosly AHB; Orlova A; Konovalova E; Schulga A; Vorobyeva A; Tolmachev V
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
    Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
    Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
    Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.
    Lai YD; Wu YY; Tsai YJ; Tsai YS; Lin YY; Lai SL; Huang CY; Lok YY; Hu CY; Lai JS
    Int J Mol Sci; 2016 Feb; 17(2):214. PubMed ID: 26861297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts.
    Kim KJ; Wang L; Su YC; Gillespie GY; Salhotra A; Lal B; Laterra J
    Clin Cancer Res; 2006 Feb; 12(4):1292-8. PubMed ID: 16489086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designed Ankyrin Repeat Proteins: A Look at their Evolving Use in Medicine with a Focus on the Treatment of Chorioretinal Vascular Disorders.
    Smithwick E; Stewart MW
    Antiinflamm Antiallergy Agents Med Chem; 2017; 16(1):33-45. PubMed ID: 28464780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
    Gordon MS; Margolin K; Talpaz M; Sledge GW; Holmgren E; Benjamin R; Stalter S; Shak S; Adelman D
    J Clin Oncol; 2001 Feb; 19(3):843-50. PubMed ID: 11157038
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction.
    Deuse T; Peter C; Fedak PW; Doyle T; Reichenspurner H; Zimmermann WH; Eschenhagen T; Stein W; Wu JC; Robbins RC; Schrepfer S
    Circulation; 2009 Sep; 120(11 Suppl):S247-54. PubMed ID: 19752375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new trivalent recombinant protein for type 2 diabetes mellitus with oral delivery potential: design, expression, and experimental validation.
    Ehsasatvatan M; Baghban Kohnehrouz B
    J Biomol Struct Dyn; 2024 Mar; ():1-16. PubMed ID: 38468545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
    Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
    Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.